Antimalarials are arguably the best modality currently available for treating patients with cutaneous lupus erythematosus (LE). Although antimalarials have been used for decades in treating cutaneous LE, the precise mechanisms by which they provide therapeutic benefit are not well defined. The putative mechanisms by which antimalarials might provide therapeutic benefit to patients with cutaneous LE include a number of interrelated anti-inflammatory and immunosuppressive effects that include photoprotection, lysosomal stabilization, suppression of antigen presentation, and inhibition of prostaglandin and cytokine synthesis. If we had a more precise understanding of how antimalarials provide therapeutic benefit in cutaneous LE we might gain better insight into the pathogenic mechanisms of LE and ways of developing better therapies for afflicted patients.
Cruz DD . Antimalarial therapy: a panacea for mild lupus?Lupus2001; 10: 148–151 .
2.
Rudnicki RD , Gresham GE , Rothfield NF . The efficacy of antimalarials in systemic lupus erythematosus . J Rheumatol1975; 2: 323–330 .
3.
The Canadian HydroxychloroquineStudy Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . New Engl J Med1991; 324: 150–154 .
4.
Tsakonas E , Joseph L , Esdaile JM et al. A long-term study of hydroxychloroquine withdrawl on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group . Lupus1998; 7: 65–67 .
5.
Jewell M , McCauliffe DP . Cutaneous lupus erythematosus patients that smoke are less responsive to antimalarial treatment . J Am Acad Dermatol2000; 42: 983–987 .
6.
Foley M , Tilley L . Quinoline antimalarials: mechanisms of action and resistance . Int J Parasitol1997; 32: 231–240 .
7.
Wallace DJ . The history of antimalarials . Lupus1996; 5(Suppl 1): S2–S3 .
8.
Loeb RF , Clark WM , Coateney GR et al. Activity of a new antimalarial agent, chloroquine (SN 7618) . JAMA1946; 130: 1069–1070 .
9.
Surrey AR , Hammer HF . Preparation of 7-chloro-4-[4-(N-ethyl, N-2hydroxyethylamino)-1-methylbutylamino]-quinoline and related compounds . J Am Chem Soc1950; 72: 1814–1815 .
10.
Ritschel WA , Hammer GV , Thompson GA . Pharmacokinetics of antimalarials and proposals for dosage regimens . Int J Clin Pharmac Ther Toxicol1978; 16: 395–401 .
11.
Laaksonen AL , Koskiahde V , Juva K . Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus . Scand J Rheumatol1974; 3: 103–108 .
12.
McChesney EW , Rothfield NF . Comperative metabolic studies of chloroquine and hydroxychloroquine . Arthritis Rheum1964; 7: 328–329 .
13.
Wallace DJ . The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination . Sem Arthritis Rheum1989; 18: 282–297 .
14.
Feldmann R , Saloman D , Saurat JH . The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus . Dermatology1994; 189: 425–427 .
15.
Lipsker D , Piette JC , Cacoub P , Godeau P , Frances C . Chloroquinequinacrine association in resistant cutaneous lupus . Dermatology1995; 190: 257–258 .
16.
Toubi E , Rosner I , Rozenbaum M , Kessel A , Golan TD . The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients . Lupus2000; 9: 92–95 .
17.
Meinao IM , Sato EI , Andrade LE , Ferraz MB , Altra E . Controlled trial with chloroquine diphosphate in systemic lupus erythematosus . Lupus1996; 5: 237–241 .
18.
Murphy GM , Hawk JL , Magnus JA . Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensivity monitoring . Br J Dermatol1987; 116: 379–386 .
19.
Epstein JH . Solar urticaria . Int J Dermatol1977; 16: 388–390 .
20.
Sharma OP . Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement . Arch Neurol1998; 55: 1248–1254 .
21.
Wallace DJ . The use of chloroquine and hydroxychloroquinefor noninfectious conditions other than rheumatoid arthritis or lupus: a critical review . Lupus1996; 5(Suppl 1): S59–S64 .
22.
Zic JA . Treatment of cutaneous sarcoidosis with chloroquine . Arch Dermatol1991; 127: 1034–1040 .
23.
Valls V , Ena J , Endriquez-de Salmanca R . Low-dose oral chloroquine with porphyria cutanea tarda . J Dermatol Sci1994; 7: 169–175 .
24.
Gottlieb B , Winklemann RK . Lymphocytic infiltration of the skin . Arch Dermatol1962; 86: 106-106 .
25.
Stritzler C . Generalized granuloma annulare (apparently responding well to chloroquine therapy) . Arch Dermatol1961; 83: 1033–1034 .
26.
Carlin MC , Ratz JL . A case of generalized granuloma annulare responding to hydroxychloroquine . Cleveland Clin J Med1967; 54: 229–232 .
27.
Brier RL , Mopper C , Stone J . Cutaneous cryptococosis; presentation of a case and review of previously reported cases . AMA Arch Dermatol1957; 75: 262–263 .
28.
Homez J . Tegumental leishmaniasis in Venezuela; presentation of several cases cured by glutantime and by synthetic antimalarials . Ann Dermatol Syph1956; 83: 271–281 .
Huff SE . Acrodermatitis chronica atrophicans; report of a case treated with chloroquine phosphate . AMA Arch Dermatol1955; 72: 132-132 .
31.
Isaacson D , Elgart M , Turner ML . Anti-malarials in dermatology . Int J Dermatol1982; 21: 379–395 .
32.
James W , Dawson N , Rodman O . The treatment of dermatomyositis with hydroxychloroquine . J Rheumatol1985; 12: 1214–1216 .
33.
Bystryn JC , Steinman NM . The adjuvant therapy of pemphigus . Arch Dermatol1996; 132: 203–212 .
34.
Alloway JA , Franks LK . Hydroxychloroquine in the treatment of chronic erythema nodosum . Br J Dermatol1995; 132: 661–662 .
35.
Worle B , Wollenbrg A , Schaller M et al. Chronic ulcerative stomatitis . Br J Dermatol1997; 137: 262–265 .
36.
Ozkaya-Bayazit E , Buyukbabani N , Baykal L et al. Annular elastolytic giant cell granuloma: sparing of a burn scar and successful treatment with chloroquine . Br J Dermatol1998; 140: 525–530 .
37.
Eisen D . Hydroxychloroquinesulfate (Plaquenil) improves oral lichen planus: an open trial . J Am Acad Dermatol1993; 28: 609–612 .
38.
Gilman AL , Beams F , Tefft M , Mazumder A . The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versushost disease . Bone Marrow Transplant1996; 17: 1069–1075 .
39.
Schultz KR , Gilman AL . The lysosomotropic amines, chloroquine and hydroxychloroquine:a potentially novel therapy for graft-versus-host disease . Leukemia & Lymphoma1997; 24: 201–210 .
40.
Kahofer P , Grabmaier E , Aberer E . Treatment of eosinophilic annular erythema with chloroquine . Acta Dermatol Venereol2000; 80: 70–71 .
41.
Balogh E , Nagy-Vezekenyi K , Forizs E . REM syndrome: an immediate therapeutic response to hydroxychloroquine sulfate . Acta Dermatol Venereol1980; 60: 173–175 .
42.
McCauliffe DP . Cutaneous lupus erythematosus . Sem Cutan Med Surg2001; 20: 14–26 .
43.
Koranda FC . Antimalarials . J Am Acad Dermatol1981; 4: 650–655 .
44.
Sjolin-Forsberg G , Berne B , Blixt C , Johansson M , Lindstrom B . Chloroquine phosphate: a long-term follow up of drug concentration in skin suction blister lfuid and plasma . Acta Dermatol Venereol1993; 73: 426–429 .
45.
Tett SE , Cutler DJ , Day RO , Brown KF . A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers . Br J Clin Pharmac1988; 26: 303–313 .
46.
Mackenzie A . Pharmacologic actions of 4-aminoquinoline compounds . Am J Med1983; 75: 11–18 .
47.
Augustijns P , Geusens P , Verbeke N . Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis . Eur J Clin Pharmac1992; 42: 429–433 .
48.
McKenzie AM , Scherbel AL . Chloroquine and hydroxychloroquinein rheumatological therapy . Clin Rheum Dis1980; 6: 545–566 .
49.
Wolheim FA , Hanson A , Laurell CB . Chloroquine treatment in rheumatoid arthritis . Scand J Rheumatol1978; 7: 171–176 .
50.
Larsson B , Tjalve H . Studies on the mechanism of drug-binding to melanin . Biochem Pharmac1979; 28: 1181–1187 .
51.
Shaffer B , Cahn MM , Levy EG . Absorption of antimalarial drugs in human skin: spectroscopic and chemical analysis in epidermis and cornium . J Invest Dermatol1958; 30: 341–345 .
52.
Fox R . Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development . Lupus1996; 5(Suppl): S4–S10 .
53.
Gonzalez-Noriega A , Grubb JH , Talkad V , Sly WS . Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by imparing receptor recycling . J Cell Biol1980; 85: 839–852 .
54.
Ignarro LJ . Dissimilar effects of antiinflammatory drugs on stability of lysosomes from peritoneal and circulating leukocytes and liver . Biochem Pharmac1971; 20: 2861-2861 .
55.
Hyttel J , Jorgensen A . Studies on lysosome stabilization by antirheumatic drugs . Eur J Pharmac1970; 11: 383-383 .
56.
Poole B , Ohkuma S . Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages . J Cell Biol1981; 90: 665–669 .
57.
Ohkuma S , Poole B . Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents . Proc Natl Acad Sci USA1978; 75: 3327–3331 .
58.
Olczyk K , Drozdz M , Kucharz E et al. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus . Rum Rom Med Med Int1984; 22: 221–225 .
59.
Toimela T , Salminen L , Tahti H . Effects of Tamoxifen, Toremifene and Chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells . Pharmac Toxicol1998; 83: 246–251 .
60.
Polet T . The effects of lysosomotrophic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes . J Cell Physiol1985; 122: 415–423 .
61.
Mountz JD , Wu J , Cheng J , Zhou T . Autoimmune disease: a problem of defective apoptosis . Arthritis Rheum1994; 37: 1415–1420 .
62.
Wanwimolruk S , Wong SM , Coville PF , Viriyayudhakorn S , Thitiarchakul S . Cigarette smoking enhances the elimination of quinine . Br J Clin Pharmac1993; 36: 610–614 .
63.
Fox R . Mechanism of action of hydroxychloroquine as an antirheumatic drug . Sem Arthritis Rheum1993; 23: 82–91 .
64.
Fox R , Kang H . Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation . Lupus1993; 2: S9–S12 .
65.
Humbert M , Bertolino P , Forquet F et al. Major histocompatibility complex class II-restricted presentation of secreted and endoplasmic reticulum resident antigens requires the invariant chains and is sensitive to lysosomotrophic agents . Eur J Immunol1993; 23: 3167–3172 .
66.
Schultz K , Bader S , Paquet J , Li W . Chloroquine treatment affects Tcell priming to minor histocompatibility antigens and graft-versushost disease . Blood1995; 86: 4344–4352 .
67.
Nowell J , Quaranta V . Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells . J Exp Med1985; 162: 1371–1376 .
68.
Bennion S , Norris D . Ultraviolet light modulation of autoantigens, epidermal cytokines and adhesion molecules as contributing factors of the pathogenesis of cutaneous LE . Lupus1997; 6: 181–192 .
69.
Ausiello C , Barberi P , Spagnoli G , Ciompi M , Casciani C . In vivo effects of chloroquine treatment on spontaneous and interferoninduced natural killer activities in rheumatoid arthritis patients . Clin Exp Rheumatol1986; 4: 255–259 .
70.
Chaicumpa W , Roca R , Atthasishtha N, Chongsuphajaisiddhi T. Effects of antimalarial drugs on human natural killer cell activity . Southeast Asian J Trop Med Public Health1983; 14: 413–419 .
71.
Forbes J , Bretthauer R , Oeltmann T . Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity . Proc Natl Acad Sci USA1981; 78: 5797–5801 .
72.
Ghoneum M , Cooper E , Smith C . Inhibition of SK cell activity in frogs by certain drugs and sugars . Devl Comp Immunol1987; 11: 363–373 .
73.
Ausiello C , Sorrentino V , Ruggiero V , Rossi G . Action of lysosomotrophic amines on spontaneous and interferon enhanced NK and CTL cytolysis . Immunol Lett1984; 8: 11–15 .
74.
Ruzicka T , Printz M . Arachidonic acid metabolism in guinea pig skin: effects of chloroquine . Agents Actions1982; 12: 527–529 .
75.
el Tahir K . Influence of niridazole and chloroquine on arterial and myometrial prostacyclin synthesis . Br J Pharmac1987; 92: 567–572 .
76.
Bryan D , Sexton CJ , Williams D , Leigh IM , McKay IA . Oral keratinocytes immortalized with the early region of human papillomavirus type 16 show elevated expression of interleukin 6, which acts as an autocrine growth factor for the derived T103C cell line . Cell Growth Diff1995; 6: 1245–1250 .
77.
Bondeson J , Sundler R . Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1b and tumor necrosis factor in macrofages: implications for their mode of action in rheumatoid arthritis . Gen Pharmac1998; 30: 357–366 .
78.
Chen X , Gresham A , Morrison A, Pentland A. Oxidative stress mediates synthesis of cytosolic phospholipase A2 after UVB injury . Biochim et Biophys Acta1996; 1299: 23–33 .
79.
Taira J , Mimura K , Yoneya T et al. Hydroxy radical formation by UV-irradiated epidermal cells . J Biol Chem1992; 111: 693–695 .
80.
Punnonen K , Puntala A , Jansen C , Ahotupa M . UVB irradiation induces lipid peroxidation and reduces antioxidant enzyme activities in human keratinocytes in vivo . Acta Dermatol Venereol1991; 71: 239–242 .
81.
Ogura R , Sugiyama M , Nishi J , Haramaki N . Mechanism of lipid radical formation following exposure of epidermal homogenate to ultraviolet light . J Invest Dermatol1991; 97: 1044–1047 .
82.
Punnonen K , Puntala A , Ahotupa M . Effects of ultraviolet A and B irradiation on lipid peroxidation and activity of the antioxidant enzymes in keratinocytes in culture . Photodermatol Photoimmunol Photomed1991; 8: 3–6 .
83.
Ramakrishnan N , Kalinich J , McClain D . Ebselen inhibition of apoptosis by reduction of peroxides . Biochem Pharmac1996; 51: 1443–1451 .
84.
Ivanina T , Sakina N , Lebedeva M , Borovyagin V . A study of the mechanisms of chloroquine retinopathy. I. Chloroquine effect on lipid peroxidation of the retina . Ophthal Res1989; 21: 216–220 .
85.
Jackson M , Jones D , Harris E . Inhibition of lipid peroxidation in muscle homogenates by phospholipase A2 inhibitors . Biosci Rep1984; 4: 581–587 .
86.
Bhattacharyya B , Chatterjee T , Ghosh J . Effects of chloroquine on lysosomal enzymes, NADPH-induced lipid peroxidation, and antioxidant enzymes of rat retina . Biochem Pharmac1983; 32: 2965–2968 .
87.
Raley M , Schwacha M , Loegering D . Lysosomotropic agents ameliorate macrophage dysfunction following the phagocytosis of IgGcoated erythrocytes: a role for lipid peroxidation . Inflammation1997; 21: 619–628 .
88.
Picot S , Peyron F , Donadille A et al. Chloroquine-induced inhibition of the production of TNF, but not IL-6, is affected by disruption of iron metabolism . Immunology1993; 80: 127–133 .
89.
Picot S , Peyron F , Vuillez JP , Polack B , Ambroise-Thomas P. Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro . J Infect Dis1991; 164: 830-830 .
90.
Ertel W , Morrison M , Ayala A , Chaudry I . Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release . Blood1991; 78: 1781–1788 .
91.
van den Borne BEEM , Dijkmans BAC , de Rooij HH , Cessie S , Verweij CL . Chloroquine and hydroxychloroquine equally affect tumor necrosis factor, interleukin 6, and interferon production by peripheral blood mononuclear cells . J Rheumatol1997; 24: 55–60 .
92.
Picot S , Nkwelle Akede A , Chaulet JF et al. Chloroquine selftreatment and clinical outcome of cerebral malaria in children . Clin Exp Immunol1997; 108: 279–283 .
93.
Zhu X , Ertel W , Ayala A et al. Chloroquine inhibits macrophage tumor necrosis factor-alpha mRNA transcription . Immunology1993; 80: 122–126 .
94.
Karres I , Kremer JP , Dietl I et al. Chloroquine inhibits proinflammatory cytokine release into human whole blood . Am J Physiol1998; 274: 1058–1064 .
95.
Sperber K , Quraishi H , Kalb TH et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1) and IL-6 in human monocytes and T cells . J Rheumatol1993; 20: 803–808 .
96.
Salmeron G , Lipsky PE . Immunosuppressive potential of antimalarials . Am J Med1983; 18: 19–24 .
97.
Landewe RB , Miltenburg AM , Breedveld FC , Daha MR , Dijkmans BA . Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis . J Rheumatol1992; 19: 1353–1357 .
98.
Corral LG , Haslett PA , Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha . J Immunol1999; 163: 380–386 .
99.
Burrows NP , Walport MJ , Hammond AH , Davey N , Jones RR . Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide . Br J Dermatol1991; 125: 62–67 .
100.
Knopp J , Bonsmann G , Happle R et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus . Br J Dermatol1983; 108: 461–466 .
101.
Ochonisky S , Verroust J , Bastuji-Garin S , Gherardi R , Revuz J . Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients . Arch Dermatol1994; 130: 66–69 .
102.
Stevens RJ , Andujar C , Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients . Br J Rheumatol1997; 36: 353–359 .
103.
Werth VP , Zhang W , Dortzbach K , Sullivan K . Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and a distinct photoregulation of transcription . J Invest Dermatol2000; 115: 726–730 .
104.
Panayi GS . The pathogenesis of rheumatoid arthritis: from molecules to the whole patient . Br J Rheumatol1993; 32: 533–536 .
105.
Krammer PH , Behrmann I , Daniel P , Dhein J , Debatin KM . Regulation of apoptosis in the immune system . Curr Opin Immunol1994; 6: 279–289 .
106.
Little G , Flores A . Inhibition of programmed cell death by cyclosporine . Comp Biochem Physiol1992; 103: 463–467 .
107.
Gottlieb R , Nordberg J , Skowronski E , Babior B . Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification . Proc Natl Acad Sci USA1996; 93: 654–658 .
108.
Potvin F , Petitclerc E , Marceau F , Poubelle PE . Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells . J Immunol1997; 158: 1872–1879 .
109.
Wolvetang EJ , Larm JA , Moutsoulas P , Lawen A . Apoptosis induced by inhibitors of the plasma membrane NADH-oxidase involves Bcl-2 and calcineurin . Cell Growth Differ1996; 7: 1315–1325 .
110.
Picot S , Burnod J , Bracchi V , Chumpitazi BF , Ambroise-Thomas P . Apoptosis related to chloroquine sensitivity of human malaria parasite Plasmodium falciparum . Trans R Soc Trop Med Hyg1997; 91: 590–591 .
111.
Meng XW , Feller JM , Ziegler JB , Pittman SM , Ireland CM . Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine . Arthritis Rheum1997; 40: 927–935 .
112.
Maeda S , Lin KH , Inagaki H , Saito T . Induction of apoptosis in primary culture of rat hepatocytes by protease inhibitors . Biochem Mol Biol Int1996; 39: 447–453 .
113.
Elkon KB . Apoptosis in SLE: too little or too much?Clin Exp Rheumatol1994; 12: 553–559 .
114.
Panayi GS , Neill WA , Duthie JJR , McCornick JN . Action of chloroquine phosphate in rheumatoid arthritis. I. Immunosuppressive effect . Ann Rheum Dis1973; 32: 316–320 .
115.
Knox J , Griffin A , Hakim RE . Effect of chloroquine on erythematous and carcinogenic response to ultraviolet light . Arch Dermatol1960; 81: 122–128 .
116.
Langlo L . The efficiency of local application of chloroquine and mepacrine in preventing the effects of ultraviolet rays on human skin . Acta Dermatol Venereol1957; 37: 85–86 .
117.
Krutmann J , Grewe M . Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression . J Invest Dermatol1995; 105: 67S–70S .
118.
Norris DA . Pathomechanisms of photosensitive lupus erythematosus . J Invest Dermatol1993; 100: 58S–68S .
119.
Sjolin-Forsberg G , Berne B , Eggelte TA , Karlsson-Parra A . In situ localization of chloroquine and immunohistological studies in UVBirradiated skin of photosensitive patients . Acta Derm Venereol1995; 75: 228–231 .
120.
van Weelden H , Bolling HH , Baart de la Faille H , van der Leun JC . Photosensitivitycaused by chloroquine . Arch Dermatol1982; 118: 290-290 .
121.
Seideman P , Ros AM . Sensitivity to UV light during treatment with chloroquine in rheumatoid arthritis . Scand J Rheumatol1992; 21: 245–247 .
122.
Sjolin-Forsberg G , Lindstrom B , Berne B . Topical chloroquine applied before irradiation protects against ultraviolet B (UVB)and UVA-induced erythema but not against immediate pigment darkening . Photodermatol Photoimmunol Photomed1992; 9: 220–224 .
123.
Juhlin L , Shroot B . Effect of drugs on the early and late phase UV erythema . Acta Dermatol Venereol1992; 72: 222–223 .
124.
Lester R , Burnham T , Fine G , Murray K . Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. The mechanism of action of hydroxychloroquine .Arch Dermatol1967; 96: 1–10 .
125.
Everett MA , Coffey CM . Intradermal administration of chloroquine for discoid lupus erythematosus and lichen sclerosis et atrophicus . Arch Dermatol1961; 83: 977–979 .
126.
Segal-Eiras A , Segura GM , Babini JC et al. Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis . J Rheumatol1985; 12: 87–89 .
127.
Miyachi Y , Yoshioka A , Imamura S , Niwa Y . Antioxidant action of antimalarials . Ann Rheum Dis1986; 45: 244–248 .
128.
Jancinova V , Nosal R , Petrikova M . On the inhibitory effect of chloroquine on blood platelet aggregation . Thromb Res1994; 74: 495–504 .
129.
Rustan AC , Nossen JO , Tefre T , Drevon CA . Inhibition of very-lowdensity lipoprotein secretion by chloroquine, verapamil, and monensin takes place in the Golgi complex . Biochim Biophys Acta1987; 930: 311–319 .
130.
Beynen AC , van den Molen AJ , Geelen MJH . Inhibition of hepatic cholesterol biosynthesis by chloroquine . Lipids1981; 16: 472–474 .
131.
Svenson KLG , Lithell H , Hallgren R , Vessby B . Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease-modifying drug treatment . Arch Intern Med1987; 147: 1917–1920 .
132.
Wallace DJ , Metzger AL , Stecher VJ , Turnbull BA , Kern PA . Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med1990; 89: 322–326 .
133.
Hodis HN , Quismorio FP , Wickham E , Blankenhorn DH . The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus . J Rheumatol1993; 20: 661–665 .
134.
Petri M , Lakatta C , Magder L , Goldman D . Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis . Am J Med1994; 96: 254–259 .
135.
Rahman P , Gladman DD , Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs . J Rheumatol1999; 26: 325–330 .
136.
Smith GD , Amos TAS , Mahler R , Peters TJ . Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus . Br Med J1987; 294: 465–467 .
137.
Blazar BR , Whitley CB , Kitabchi AE et al. In vivo chloroquineinduced inhibition of insulin degradation in a diabetic patient with severe insulin resistance . Diabetes1984; 33: 1133–1136 .
138.
Dennis PA , Aronson JNN . The effects of low temperature and chloroquine on 1251-insulin degradation by the perfused rat liver . Arch Biochem Biophys1981; 212: 170–176 .
139.
Quatraro A , Consoli G , Magno M et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug . Ann Intern Med1990; 112: 678–681 .
140.
Petri M . Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis . Lupus1996; 5(Suppl 1): S16–S22 .
141.
Abu-Shakra M , Lee P . Hypoglycemia: an unusual adverse reaction to chloroquine . Clin Exp Rheumatol1994; 12: 95-95 .
142.
Bamber MG , Redapth A . Chloroquine and hypoglycemia . Lancet1987; i: 1211-1211 .
143.
Shojania K , Koehler BE , Elliott T . Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis . J Rheumatol1999; 26: 195–196 .
144.
Weber SM , Levitz SM . Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotrophic mechanism . J Immunol2000; 165: 1534–1540 .
145.
Sontheimer R , Maddison P , Reichlin M et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus . Ann Int Med1982; 97: 664–671 .
146.
Johansson-Stephansson E , Koskimes S , Partanen J , Kariniemi AL . Subacute cutaneous lupus erythematosus: genetic markers and clinical and immunological findings in patients . Arch Dermatol1989; 125: 791–796 .
147.
Watson RM , Talwar P , Alexander E , Bias WB , Provost TT . Subacute cutaneous lupus erythematosus-immunogenetic associations . J Autoimmun1991; 4: 73–85 .
148.
Sullivan KE , Wooten C , Schmeckpeper BJ , Goldman D , Petri MA . A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans . Arthritis Rheum1997; 40: 2207–2211 .
149.
Carter AE , Eban R , Perret RD . Prevention of post-operative deep venous thrombosis and pulmonary embolism . Br Med J1971; 1: 312–314 .
150.
Carter AE , Eban R . Prevention of postoperative deep venous thrombosis in leg by orally administered hydroxychloroquine sulfate . Br Med J1974; 3: 94–95 .
151.
Wallace D . Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?Arthritis Rheum1987; 30: 1435–1436 .
